MX2023001157A - Anti-integrin beta7 antibody formulations and devices. - Google Patents

Anti-integrin beta7 antibody formulations and devices.

Info

Publication number
MX2023001157A
MX2023001157A MX2023001157A MX2023001157A MX2023001157A MX 2023001157 A MX2023001157 A MX 2023001157A MX 2023001157 A MX2023001157 A MX 2023001157A MX 2023001157 A MX2023001157 A MX 2023001157A MX 2023001157 A MX2023001157 A MX 2023001157A
Authority
MX
Mexico
Prior art keywords
devices
integrin beta7
beta7 antibody
antibody formulations
formulations
Prior art date
Application number
MX2023001157A
Other languages
Spanish (es)
Inventor
Jennifer Pulley
Meina Tao Tang
Swati Tole
Helen Tyrrell
Mariam Abouhossein
Hemanth Amarchinta
Audrey Boruvka
Han Ting Ding
Heather L Flores
Glen Scott Giese
Renato Ravanello
Wenhui Zhang
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of MX2023001157A publication Critical patent/MX2023001157A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

Formulations comprising an anti-integrin beta7 antibody or an antigen-binding fragment thereof are provided, including pharmaceutical formulations. Also provided are article of manufactures comprising such formulations, and methods of using such formulations.
MX2023001157A 2020-07-31 2021-07-29 Anti-integrin beta7 antibody formulations and devices. MX2023001157A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063059427P 2020-07-31 2020-07-31
PCT/US2021/043690 WO2022026699A1 (en) 2020-07-31 2021-07-29 Anti-integrin beta7 antibody formulations and devices

Publications (1)

Publication Number Publication Date
MX2023001157A true MX2023001157A (en) 2023-02-22

Family

ID=77693570

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023001157A MX2023001157A (en) 2020-07-31 2021-07-29 Anti-integrin beta7 antibody formulations and devices.

Country Status (11)

Country Link
EP (1) EP4188958A1 (en)
JP (1) JP2023536158A (en)
KR (1) KR20230041071A (en)
AR (1) AR123085A1 (en)
AU (1) AU2021316017A1 (en)
BR (1) BR112023001734A2 (en)
CA (1) CA3190109A1 (en)
IL (1) IL300133A (en)
MX (1) MX2023001157A (en)
TW (1) TW202222832A (en)
WO (1) WO2022026699A1 (en)

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
AU633698B2 (en) 1990-01-12 1993-02-04 Amgen Fremont Inc. Generation of xenogeneic antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
WO1992003918A1 (en) 1990-08-29 1992-03-19 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
EP0861893A3 (en) 1991-09-19 1999-11-10 Genentech, Inc. High level expression of immunoglobulin polypeptides
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
EP1978033A3 (en) 1995-04-27 2008-12-24 Amgen Fremont Inc. Human antibodies derived from immunized xenomice
CA2219486A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
CA2616914C (en) 1996-12-03 2012-05-29 Abgenix, Inc. Egfr-binding antibody
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
KR100797667B1 (en) 1999-10-04 2008-01-23 메디카고 인코포레이티드 Method for regulating transcription of foreign genes
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
DE60139944D1 (en) 2000-10-12 2009-10-29 Genentech Inc LOW VISCOSIS CONCENTRATED PROTEIN FORMULATIONS
US20050158303A1 (en) 2003-04-04 2005-07-21 Genentech, Inc. Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations
PT2322556E (en) 2004-09-03 2016-02-15 Genentech Inc Humanized anti-beta7 antagonists and uses therefor
PL2279004T3 (en) 2008-05-16 2015-06-30 Hoffmann La Roche Use of biomarkers for assessing treatment of gastrointestinal inflammatory disorders with beta7integrin antagonists
EP2403874A1 (en) 2009-03-06 2012-01-11 Genentech, Inc. Antibody formulation
UY34054A (en) * 2011-05-02 2012-11-30 Millennium Pharm Inc FORMULATION FOR ANTI-A ANTIBODY (alpha) 4B (Beta) 7
CN103732276B (en) 2011-06-17 2015-11-25 Shl集团有限责任公司 Injection device
RU2578178C2 (en) 2011-06-17 2016-03-20 Схл Груп Аб Injector
JP6615745B2 (en) 2013-03-27 2019-12-04 ジェネンテック， インコーポレイテッド Use of biomarkers to evaluate treatment of gastrointestinal inflammatory disorders with beta7 integrin antagonists
SG11201607938UA (en) 2014-03-27 2016-10-28 Genentech Inc Methods for diagnosing and treating inflammatory bowel disease
JP2018507868A (en) * 2015-02-26 2018-03-22 ジェネンテック， インコーポレイテッド Integrin beta 7 antagonist and method of treating Crohn's disease
EP3810085A1 (en) * 2018-06-20 2021-04-28 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an integrin inhibitor

Also Published As

Publication number Publication date
JP2023536158A (en) 2023-08-23
IL300133A (en) 2023-03-01
AU2021316017A1 (en) 2023-02-16
BR112023001734A2 (en) 2023-02-28
WO2022026699A1 (en) 2022-02-03
KR20230041071A (en) 2023-03-23
TW202222832A (en) 2022-06-16
EP4188958A1 (en) 2023-06-07
AR123085A1 (en) 2022-10-26
CA3190109A1 (en) 2022-02-03

Similar Documents

Publication Publication Date Title
MX2020012797A (en) Anti-pvrig/anti-tigit bispecific antibodies and methods of use.
PH12019501973A1 (en) Anti-phf-tau antibodies and uses thereof
MX2021015024A (en) Neutralizing anti-sars-cov-2 antibodies and methods of use thereof.
MX2021000347A (en) High-affinity, isoform-selective tgfî²1 inhibitors and use thereof.
EP4282489A3 (en) Treatment of clostridium difficile infection
MX2022004304A (en) Apoptosis-inducing agents.
MX2020003939A (en) Mdm2 inhibitors and therapeutic methods using the same.
MY191581A (en) Anti-pd-1 antibodies
MX2019001471A (en) Anti-siglec-7 antibodies for the treatment of cancer.
PH12020500576A1 (en) Method of treating cancers with antagonistic anti-pd-1 antibodies
PH12020551716A1 (en) Anti-ror antibody constructs
WO2020051333A8 (en) Anti-avb8 antibodies and compositions and uses thereof
WO2020014473A8 (en) TGFβ1 INHIBITORS AND USE THEREOF
MX2020008122A (en) Anti-pd-1 antibodies.
MX2022014457A (en) Stable anti-cd79b immunoconjugate formulations.
CR20220216A (en) Heteroaryl-biphenyl amines for the treatment of pd-l1 diseases
AU2017248276A1 (en) Methods of treating ocular conditions
MX2022003212A (en) Anti-klk7 antibodies, anti-klk5 antibodies, multispecific anti-klk5/klk7 antibodies, and methods of use.
MX2023014458A (en) Anti-ccr8 antibodies and uses thereof.
MX2021010254A (en) Antibody-drug conjugates comprising anti-tm4sf1 antibodies and methods of using the same.
MX2020013389A (en) Terlipressin compositions and uses thereof.
WO2022034524A3 (en) Antibodies against ilt2 and use thereof
MX2022015966A (en) Antibodies and methods for treating claudin-associated diseases.
MX2022006784A (en) Anti-pd-l1 antibody formulations.
WO2017161344A8 (en) Compositions and methods for treating parasitic diseases